Specifically, previous studies have suggested that plasma levels of Aβ, tau, and other target proteins, such as neurofilament light, amyloid precursor protein, and others, are altered in patients with AD and those in the prodromal stage of AD, mild cognitive impairment (MCI). Here, MAPT is linked to Alzheimer disease.